
Mandy Jackson
Managing Editor, US Commercial News at Scrip
Managing Editor, US Commercial News at The Pink Sheet
I am Managing Editor, US Commercial News, for the Citeline Commercial publication Scrip. Views expressed here are strictly my own.
Articles
-
2 days ago |
insights.citeline.com | Sarah Karlin-Smith |Sarah Karlin-Smith |Mandy Jackson |Mary Jo Laffler
Post-BIO Podcast: Thoughts From The FrontlinesScrip and Pink Sheet journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry. Scrip and Pink Sheet editors discuss this year's BIO meeting. • Source: Shutterstock
-
1 week ago |
insights.citeline.com | Mandy Jackson |Joseph Haas
BIO Notebook: Policy Uncertainty Contraining DealmakingHighlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
-
1 week ago |
insights.citeline.com | Mandy Jackson |Joseph Haas |Sarah Karlin-Smith |Sarah Karlin-Smith
BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains ConstrainedUpdates From Day 4 Of BIO Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program
1 week ago |
insights.citeline.com | Sarah Karlin-Smith |Sarah Karlin-Smith |Mandy Jackson |Alaric DeArment
BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review ProgramUpdates From Day 3 Of BIOHighlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
-
1 week ago |
insights.citeline.com | Sarah Karlin-Smith |Sarah Karlin-Smith |Mandy Jackson
BIO Notebook: Policy Problems, ACIP’s Future, BI Is Popular, Makary On FDA-Industry Ties Highlights from Day Two of the BIO International Convention include BIO officials raising concerns about Trump Administration policies, the future of ACIP, an interview with BI's head of global business development, and FDA Commissioner Martin Makary's view of the FDA-industry relationship.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 5K
- Tweets
- 17K
- DMs Open
- No

$CYTK Down about 14% after hours

$CYTK Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy DEC 26, 2025 https://t.co/mxJouiO4BL

RT @MSollender: $XNCR Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Ex…

RT @PharmaScrip: The 2025 Scrip Awards Is Open For Entries https://t.co/80dOrbC7V2 #PharmaScrip https://t.co/D7y0NY4Ym5